The USFDA has recently approved
GlaxoSmithKline (NYSE:
GSK)’s antibacterial
Altabax™ (a pdf file) for the topical treatment of
impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes - the two most common types of bacteria in this kind of infection.
Impetigo is a highly contagious infection of the top layers of the skin and is most common among infants and children ages 2 to 6 years. Children are especially susceptible to infections because their immune systems are still developing. Impetigo spreads easily in schools and child care settings, as well as anywhere groups of people are in close contact.
In the past two decades, Altabax™ is the first new class of prescription topical antibacterials (called pleuromutilins) to be approved by the USFDA and is indicated for use twice daily for a five-day period in patients nine months of age and older.
Find more details from the full report.
.jpg)
What other bacterial infections can be treated by Altabax ?
Posted by: Anonymous | October 19, 2007 12:30 PM | Permalink to Comment